Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...
The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...
Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...
China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...
China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...
The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...